Evogene Future Growth

NasdaqCM:EVGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	60	-5	N/A	N/A	1
12/31/2025	32	-17	N/A	N/A	1
12/31/2024	17	-21	N/A	N/A	1
12/31/2023	6	-24	-22	-22	N/A
9/30/2023	6	-20	-19	-18	N/A
6/30/2023	2	-23	-22	-21	N/A
3/31/2023	2	-25	-23	-22	N/A
12/31/2022	2	-27	-25	-24	N/A
9/30/2022	1	-31	-31	-30	N/A
6/30/2022	1	-32	-29	-28	N/A
3/31/2022	1	-29	-29	-28	N/A
12/31/2021	1	-28	-26	-25	N/A
9/30/2021	1	-29	-24	-24	N/A
6/30/2021	1	-26	-23	-22	N/A
3/31/2021	1	-24	-19	-19	N/A
12/31/2020	1	-23	-20	-20	N/A
9/30/2020	1	-21	-18	-17	N/A
6/30/2020	1	-21	-18	-17	N/A
3/31/2020	0	-21	-19	-18	N/A
12/31/2019	1	-18	-19	-18	N/A
9/30/2019	1	-18	-16	-16	N/A
6/30/2019	2	-18	-16	-16	N/A
3/31/2019	2	-19	-16	-16	N/A
12/31/2018	2	-21	-16	-15	N/A
9/30/2018	2	-21	-16	-16	N/A
6/30/2018	2	-21	-16	-15	N/A
3/31/2018	3	-21	-16	-16	N/A
12/31/2017	3	-21	-17	-16	N/A
9/30/2017	4	-21	N/A	-17	N/A
6/30/2017	5	-21	N/A	-16	N/A
3/31/2017	5	-21	N/A	-15	N/A
12/31/2016	7	-20	N/A	-12	N/A
9/30/2016	8	-18	N/A	-12	N/A
6/30/2016	9	-17	N/A	-11	N/A
3/31/2016	10	-17	N/A	-12	N/A
12/31/2015	11	-17	N/A	-12	N/A
9/30/2015	12	-17	N/A	-10	N/A
6/30/2015	12	-17	N/A	-9	N/A
3/31/2015	13	-16	N/A	-8	N/A
12/31/2014	15	-15	N/A	-9	N/A
9/30/2014	17	-14	N/A	-8	N/A
6/30/2014	18	-12	N/A	-7	N/A
3/31/2014	18	-11	N/A	-6	N/A
12/31/2013	15	-9	N/A	-5	N/A
9/30/2013	18	-5	N/A	-5	N/A
6/30/2013	18	-4	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVGN's revenue (62.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: EVGN's revenue (62.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EVGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Evogene Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased to US$6.00

Price target decreased to US$10.33

Price target decreased to US$10.33

Price target raised to US$15.00

Recent updates

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$6.00

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Evogene unit launches 2nd-gen medical cannabis products in Israel

Lavie Bio appoints Guri Oron as CEO

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene regains compliance with Nasdaq's minimum bid price requirement

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

Price target decreased to US$10.33

High number of new directors

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Price target decreased to US$10.33

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Evogene EPS beats by $0.01, beats on revenue

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

Price target raised to US$15.00

New 90-day high: US$7.68

New 90-day high: US$5.95

New 90-day high: US$5.63

Evogene unit - Canonic inks cultivation deal for medical cannabis varieties

AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program

New 90-day high: US$4.31

Evogene: Q3 Update And Upcoming Catalysts

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

New 90-day high: US$4.16

New 90-day high: US$3.09

First half earnings released

New 90-day high - US$1.33

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts